LongEveron Announces Updated Phase 2b Trial Results for Laromestrocel
LongEveron announced updated results from its Phase 2b ELPIS II clinical trial evaluating laromestrocel as a potential treatment for hypoplastic left heart syndrome.
LongEveron announced updated results from its Phase 2b ELPIS II clinical trial evaluating laromestrocel as a potential treatment for hypoplastic left heart syndrome.